Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b

We conducted an open-labeled clinical trial of interferon beta-1b (IFNB) treatment in 20 patients with primary progressive multiple sclerosis (PPMS) and longitudinally monitored autoantibodies against double-stranded DNA (dsDNA), thyroid peroxidase (TPO),myelin basic protein (MBP), myelin oligodendr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology 2004-12, Vol.251 (12), p.1498-1501
Main Authors: BITSCH, Andreas, DRESSEL, Alexander, MEIER, Kathrin, BOGUMIL, Timon, DEISENHAMMER, Florian, TUMANI, Hayrettin, KITZE, Bernd, POSER, Sigrid, WEBER, Frank
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - therapeutic use
Adult
Autoantibodies - biosynthesis
Autoantibodies - blood
Biological and medical sciences
DNA - immunology
Female
Humans
Immunomodulators
Interferon beta-1b
Interferon-beta - immunology
Interferon-beta - therapeutic use
Iodide Peroxidase - immunology
Male
Medical sciences
Middle Aged
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Multiple Sclerosis, Chronic Progressive - drug therapy
Multiple Sclerosis, Chronic Progressive - immunology
Neurology
Pharmacology. Drug treatments
Recombinant Proteins - immunology
Recombinant Proteins - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We conducted an open-labeled clinical trial of interferon beta-1b (IFNB) treatment in 20 patients with primary progressive multiple sclerosis (PPMS) and longitudinally monitored autoantibodies against double-stranded DNA (dsDNA), thyroid peroxidase (TPO),myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), synapsin and S-100B. Before treatment, one patient had elevated TPO antibodies, four patients had elevated antibodies against S-100B, two patients against MOG or synapsin and one patient against MBP. In two patients we observed a continuous increase of dsDNA or TPO antibodies above the normal range. This rise paralleled IFNB treatment. In addition, 11 of 20 patients developed neutralizing antibodies against IFNB. There was no increase of autoantibodies directed against central nervous system antigens. Like patients with relapsing remitting or secondary progressive multiple sclerosis, PPMS patients may be at risk of an autoimmune response during IFNB treatment.
ISSN:0340-5354
1432-1459
DOI:10.1007/s00415-004-0580-3